SecBot SecBot
SECBOTREPLAY Home › Report › NKTX

NKTX · Nkarta reported Q2 2026 net loss of $0.54 per share, significantly…

Nkarta, Inc. · 8-K filed Aug 10, 2026 at 16:12 ET

At the news

BEARISHIMPACT 6/10

8-K filed Aug 10, 2026 at 16:12 ET

Nkarta reported Q2 2026 net loss of $0.54 per share, significantly missing the consensus estimate of -$0.36 per share. The net loss widened to $40.4 million from $23.0 million a year ago, driven by a 59% increase in operating expenses, including an $8.0 million impairment charge. Cash burn accelerated, with cash and investments declining to $243.2 million from $295.1 million at year-end 2025, though the company maintains a cash runway into 2029. No clinical data catalysts were announced, with initial data still expected at a medical conference in 2026.

  • Net loss per share was -$0.54 vs consensus -$0.36, a 48.6% miss.
  • Net loss widened to $40.4M in Q2 2026 from $23.0M in Q2 2025.
  • Operating expenses surged 59% YoY to $43.1M, including an $8.0M impairment charge.
  • Cash and investments fell to $243.2M from $295.1M at Dec 31, 2025, a $51.9M decline in six months.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access